ICON Public Limited Company

NASDAQ:ICLR

Medical - Diagnostics & Research

Healthcare
$195.16 -0.19%

-$0.27 today

Market cap
$14.62B
Beta
1.27
P/E (TTM)
23.0
EPS (TTM)
$6.23
52W Low $66.57High $211.00

Volume 0.55M

Average 1.15M

ICLR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ICON Public Limited CompanyNASDAQ: ICLR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How ICLR compares with its peers on the latest reported figures

  • ICLR's LTM Jun 2026 research & development of $0 is the highest of the 6 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for ICLR, versus a peer median of 0.0%.
ICLR Competitors Peer median
Research & Development for ICLR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ICLRICON Public Limited CompanyLTM Jun 2026$0 ——0.0%
IQVIQVIA Holdings Inc.LTM Jun 2026$0 ——0.0%
LHLabcorp Holdings Inc.LTM Jun 2026$0 ——0.0%
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$0 ——0.0%
FTREFortrea Holdings Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding ICLR) $0——0.0%

Competitors are the stored peer set for ICLR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.48B7.74B8.12B8.28B8.25B
Cost of Revenue3.97B5.53B5.72B5.85B6.08B
Gross Profit1.51B2.21B2.4B2.44B2.18B
Gross Margin27.5%28.6%29.6%29.4%26.4%
Research & Development00000
Selling, General & Admin585.33M778.75M776.36M728.35M780.14M
Operating Expenses1.13B1.42B1.44B1.34B1.16B
Depreciation & Amortization314.99M569.51M585.95M488.5M383M
EBITDA694.09M1.37B1.52B1.56B823.57M
EBITDA Margin12.7%17.7%18.7%18.9%10.0%
Operating Income378.53M795.24M956.15M1.1B1.01B
Operating Margin6.9%10.3%11.8%13.3%12.3%
Interest Income574K2.35M5.01M8.61M7.11M
Interest Expense182.42M229.73M336.7M237.24M188.11M
Other Income / Expenses(184.01M)(230.52M)(331.69M)(228.63M)(759.99M)
Income Before Tax194.52M564.72M624.08M869.18M252.47M
Pre-Tax Margin3.5%7.3%7.7%10.5%3.1%
Income Tax Expense41.33M59.41M11.75M77.71M23.13M
Net Income153.19M505.3M612.34M791.47M229.34M
Net Margin2.8%6.5%7.5%9.6%2.8%
EPS (Basic)2.286.207.469.602.92
EPS (Diluted)2.256.137.409.532.90
Weighted Avg Shares67.11M81.53M82.1M82.48M78.42M
Weighted Avg Shares (Diluted)68.07M82.47M82.72M83.03M78.97M

ICON Public Limited Company

NASDAQ:ICLR

Intrinsic Alpha fair value

Locked

Current Price

$195.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.